AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05758077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Cytopheretic Device
Description: The Selective Cytopheretic Device (SCD) is comprised of tubing, connectors, and a synthetic hollow fiber membrane cartridge. The device is connected in series to a commercially available CKRT hemofilter. Blood from the CKRT circuit is diverted after the CKRT hemofilter through to the extracapillary space (ECS) of the SCD cartridge. Blood circulates through the SCD ECS and then it is returned to the patient via the venous return line of the CKRT circuit. Regional citrate anticoagulation is used for the entire CKRT and SCD blood circuit.~The SCD cartridge incorporates a synthetic hollow fiber membrane with the ability to bind activated leukocytes to its extracapillary surface; and when used in a CKRT extracorporeal circuit in the presence of regional citrate anticoagulation, the SCD modulates inflammation.
Study NCT05758077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care CKRT for the subject's condition, as appropriate
Study NCT06658444 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham ultrasound
Description: sham ultrasound
Study NCT06661174 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function
Study NCT06661174 — intervention group
Intervention type: OTHER
Intervention: Non-surgical therapy
Description: Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.
Study NCT06353334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide and Sodium Chloride Injection
Description: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP twice daily. Each patient will receive continuous medication for 14 days.
Study NCT04421079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Trans-resveratrol
Description: 150mg, 300mg, 450mg
Study NCT06658717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational product (IP): Natural orange extract
Description: Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
Study NCT06353334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
Study NCT06658717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Group II: Placebo: Microcrystalline cellulose (MCC)
Description: Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
Study NCT05611346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The experimental group will receive 2 standardized hypnosis sessions via the superhero costume technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording
Study NCT06658652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide decanoate
Description: Oral tablet
Study NCT04421079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concord grape juice
Description: 8 oz, 16 oz, 24 oz
Study NCT04421079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed polyphenol extract
Description: 450mg, 900mg, 1200mg
Study NCT05396638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will be paid for abstinence at each study visit.
Study NCT04421079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
Study NCT05331170 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Research Grade RG-RV
Description: Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
Study NCT06659549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAL-101
Description: Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
Study NCT06659549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
Study NCT06659159 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric ultrasound
Description: The sequence in which the study is conducted will be as follows, the first examination (baseline examination) will take place immediately before the appointment and prescription of GLP-1 Analoga (before the first injection). During the examination the gastric content (quality/quantity) will be determined, secondly, a baseline for gastric emptying time after oral intake of 500ml of water is collected (patient drinks water, the stomach emptying will simultaneously be tracked with gastric ultrasound).~In accordance with the first endocrinological control examination (6-8 weeks after therapy initiation) the same gastric ultrasound examination is performed.
Study NCT06587334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: SRP alone
Study NCT06587334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nd: YAG Laser Assisted SRP
Description: the patients receive SRP combined with Nd: YAG laser
Study NCT06660576 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cholecystectomy and histochemical analysis of Gallbladder stones
Description: Cholecystectomy and histochemical analysis of Gallbladder stones
Study NCT06658262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercises With Cycling Exercises
Description: Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. Participants will be assisted to safely mount the ergometer bicycle. The height of the seat will be adjusted to ensure postural balance, upright seating and firm contact of the feet with the pedals. Treatment for the cycling will last for 30 minutes per session.
Study NCT06658262 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tai Chi Exercises Alone
Description: Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. 5.Part the Wild Horse's Mane
Study NCT05088876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded withdrawal of regular co-medication with paracetamol
Study NCT05088876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol in the dose already used
Study NCT06458049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Session
Description: On-line educational session-3 modules-1 hour each for a total of 3 hours
Study NCT06458049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching Call
Description: Single Coaching phone call at one month
Study NCT06458049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials
Description: Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer
Study NCT05937425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LungCaNN
Description: The needs of the patients included in the study will be determined with the supportive care needs scale. A training booklet will be given to the patients in the intervention group and they will be informed about the existing or newly formed unsupported care needs, the evaluation of their frequency and severity, and the ability of the patients to call the navigator nurse 24/7 or send an SMS. For interventions that can be applied in line with evidence-based guidelines for unsupported care needs with patients included in the intervention group every week for 12 weeks, a face-to-face navigation will be made by the navigator nurse over the phone and once a month.
Study NCT05933265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-184
Description: LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.
Study NCT05933265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: To evaluate the safety and tolerability of LP-184 as monotherapy and when administered with spironolactone (SP) in subjects with recurrent (IDH) wildtype glioblastoma.
Study NCT06238479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4101174
Description: Intravenous
Study NCT06510322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.
Study NCT06510322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched capsule not containing any medication
Study NCT04770233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early ACL reconstruction
Description: ACL reconstruction followed by rehabilitation
Study NCT04770233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active rehabilitation
Description: Non-operative treatment with active rehabilitation led by a physiotherapist with optional delayed surgery if indicated.
Study NCT06519279 — intervention group
Intervention type: DEVICE
Intervention: Opals
Description: Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.
Study NCT06661668 — intervention group
Intervention type: DEVICE
Intervention: Gastric pacemaker (Enterra system) implantation
Description: Laparascopic implantation of a gastric pacemaker (Enterra system) for patients with therapy refractive gastroparesis
Study NCT06660615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIDWIFE-LED CARE
Description: The birth process will be followed by the same midwife from the beginning of the intrapartum period until the birth of the baby and placenta. In this process, positive respectful maternal care will be included in line with the recommendations of WHO (İsbir \& Sercekuş, 2017).
Study NCT06607497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention using an AI enabled risk communication tool (PERDICT.AI)
Description: Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.
Study NCT06607497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)
Description: The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.
Study NCT06661928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Papilla preservation flap
Description: Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used.~Suturing will be performed with external vertical mattress sutures to achieve primary intention closure.
Study NCT06661928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Widman flap procedure
Description: Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures.
Study NCT06008418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The LINE Chatbot
Description: The chatbot approach is selected as it uses artificial intelligence to simulate conversations with users. The information can be collected or distributed and even through these conversations trigger human actions. LINE is one of the most widely used freeware applications in Taiwan and its chatbot function is well-organized and relatively easy to modify, adapt, and use. The design of the chatbot aims at the two elements above, ensuring goal alignment and enhancing power sharing, by guiding participants to complete three activities: specifying their goals for today's discussions, providing patient-reported outcomes by self-rating their health-related quality of life, and learning question prompt list based on their needs.
Study NCT06660303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Preoperative Education for Enhanced Recovery in Colorectal Surgery
Description: The intervention in this study involves preoperative patient education aimed at improving outcomes for individuals undergoing colorectal surgery. Patients in the study group will receive targeted educational sessions that focus on setting expectations, managing anxiety, understanding pain control, and preparing for the surgical process as part of the Enhanced Recovery After Surgery (ERAS) protocol. This educational approach is designed to empower patients, reduce anxiety, enhance satisfaction, and potentially improve post-surgical recovery compared to those receiving routine hospital care.
Study NCT06660303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine hospital care
Description: The control group, designated as Group II, will receive standard hospital care, encompassing the usual preoperative and postoperative procedures provided by the hospital. This includes typical preparation and recovery guidelines without any added specialized preoperative education or targeted nursing instructions. This routine hospital care serves as a baseline, allowing for a direct comparison of outcomes against the intervention group, which will receive comprehensive preoperative education aimed at enhancing recovery and improving surgical outcomes.
Study NCT06658743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Medical Appointments
Description: Participants will attend 4 quarterly appointments. In addition to time with their clinician, they will also have group activities that address relevant topics.
Study NCT06658743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Multidisciplinary team based care every 3 months.
Study NCT06607744 — intervention group
Intervention type: DRUG
Intervention: Pharmacokinetic profiles of Selegiline TDS and EMSAM
Description: Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.
Study NCT05151445 — intervention group
Intervention type: BEHAVIORAL
Intervention: mHealth dietary app + health coaching intervention
Description: The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart.
Study NCT06519279 — intervention group
Intervention type: DEVICE
Intervention: Axivity
Description: At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days.~The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use:~The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering.~The sensor is waterproof and can be worn during showering.
Study NCT05737602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3RP-VHL
Description: An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.
Study NCT06352632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-dose intravenous tenecteplase
Description: Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation
Study NCT06352632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous tenecteplase
Description: Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation
Study NCT06352632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intravenous tenecteplase
Description: No intravenous tenecteplase only in subjects on direct oral anticoagulant (DOACs) or those planned for emergency endovascular thrombectomy (EVT)
Study NCT06352632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative Blood Pressure Control
Description: No or minimal Systolic Blood Pressure (SBP) control; SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP (≥180mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
Study NCT06352632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Blood Pressure Control
Description: SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP (150-160mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
Study NCT06352632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Blood Pressure Control
Description: SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher after endovascular thrombectomy (EVT); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
Study NCT06352632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100 mL of 0.9% normal saline, administered as a single IV infusion with a 20-minute dosing duration.